Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 3/20 | 0.63 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.63 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.63 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | DRD3 | P35462 | 1/20 | 0.63 |
| ▸ | XDH | P47989 | 1/20 | 0.63 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.63 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenine SCHEMBL7002960 | 1.00 | PI4KA (0.63) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL1023306 | 1.00 | PI4KA (0.63) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL18189917 | 1.00 | PI4KA (0.63) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL2167068 | 1.00 | PI4KA (0.63) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Guanine SCHEMBL37966 | 0.89 | PNP (0.59) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL4579097 | 0.85 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Hypoxanthine SCHEMBL16096397 | 0.85 | ALDH1A1 (0.58) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| 2,6-Diaminopurine SCHEMBL23292805 | 0.84 | PNP (0.53) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Guanine SCHEMBL2636587 | 0.83 | PNP (0.51) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL6227732 | 0.81 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115287272-A | Novel dye decoloring method for clone and recombinase of DyP-type peroxidase gene | 浙江省农业科学院 | 2022-11-04 | — | — | CN | claimed |
| EP-3512860-A1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB Pharma Inc. (CA) | 2019-07-24 | — | — | EP | claimed |
| US-20180208924-A1 | METHOD FOR INTRODUCING SITE-DIRECTED RNA MUTATION, TARGET EDITING GUIDE RNA USED IN THE METHOD AND TARGET RNA-TARGET EDITING GUIDE RNA COMPLEX | FUKUOKA UNIVERSITY (JP) | 2018-07-26 | — | — | US | claimed |
| WO-2018049534-A1 | NUCLEOSIDE AND NUCLEOTIDE ANALOGUES BEARING A QUATERNARY ALL-CARBON STEREOGENIC CENTER AT THE 2' POSITION AND METHODS OF USE AS A CARDIOPROTECTIVE AGENT | LCB PHARMA INC. (CA) | 2018-03-22 | — | — | WO | claimed |
| WO-2024145248-A1 | COMPOSITIONS AND METHODS FOR GENERATING CIRCULAR RNA | LEVATIO THERAPEUTICS, LLC (US) | 2024-07-04 | — | — | WO | disclosed |
| CN-116322642-A | Polysaccharide derivative, polysaccharide derivative-drug conjugate, and method for producing same | 国立大学法人东京大学 | 2023-06-23 | — | — | CN | disclosed |
| CN-115287272-A | Novel dye decoloring method for clone and recombinase of DyP-type peroxidase gene | 浙江省农业科学院 | 2022-11-04 | — | — | CN | disclosed |
| US-11279736-B2 | Conformationally-preorganized, MiniPEG-containing gamma-peptide nucleic acids | CARNEGIE MELLON UNIVERSITY (US) | 2022-03-22 | — | — | US | disclosed |
| US-20210214397-A1 | CONFORMATIONALLY-PREORGANIZED, MiniPEG-CONTAINING GAMMA-PEPTIDE NUCLEIC ACIDS | CARNEGIE MELLON UNIVERSITY (US) | 2021-07-15 | — | — | US | disclosed |
| CN-110430897-B | Conjugation unit and molecular construct comprising same | 免疫功坊股份有限公司 | 2021-01-22 | — | — | CN | disclosed |
| US-20200364229-A1 | PARALLELIZABLE SEQUENCE ALIGNMENT SYSTEMS AND METHODS | SAMSUNG ELECTRONICS CO LTD (KR) | 2020-11-19 | — | — | US | disclosed |
| CN-111867626-A | Methods and compositions for treating amyloid deposition diseases | 纽约哥伦比亚大学理事会 | 2020-10-30 | — | — | CN | disclosed |
| WO-2007103814-A2 | ANGIOGENESIS PATHWAY GENE POLYMORPHISMS FOR THERAPY SELECTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070207486-A1 | determining whether a patient will respond to anti-VEGF antibody based chemotherapy by screening suitable cell or tissue sample from the patient for at least one genomic polymorphism or genotype; using a bevacizumab antibody or an antibody that binds to the same epitope on VEGF and and cyclophosphamide | UNIVERSITY OF SOUTHERN CALIFORNIA | 2007-09-06 | — | — | US | disclosed |
| CN-1753687-A | Use of cpg oligonucleotides in the treatment of hepatitis c virus infection | COLEY PHARMACEUTICAL GROUP LTD (CA) | 2006-03-29 | — | — | CN | disclosed |
| EP-1005478-A1 | RIBONUCLEOSIDE-DERIVATIVE AND METHOD FOR PREPARING THE SAME | Pitsch, Stefan (CH) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999009044-A1 | RIBONUCLEOSIDE-DERIVATIVE AND METHOD FOR PREPARING THE SAME | PITSCH STEFAN (CH) | 1999-02-25 | — | — | WO | disclosed |
| US-5780607-A | PYRANOSYL NUCLEOSIDE MONOMER UNITS CONNECTED BY AMIDE LINKAGES | HOFFMANN-LA ROCHE INC. (US) | 1998-07-14 | — | — | US | disclosed |
| US-5730940-A | DETECTION DNA BASE ARRANGEMENT | MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1998-03-24 | — | — | US | disclosed |
| US-4997818-A | Using a nitrogenous heterocyclic base and dideoxy-pentose monosaccharides | THE UNIVERSITY HOSPITAL (US) | 1991-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279736-B2 | Conformationally-preorganized, MiniPEG-containing gamma-peptide nucleic acids | POLL, PCNA, POLG | PI4KA 1915/4885PI4K2B 2188/4885PI4K2A 2663/4885 |
| US-20210214397-A1 | CONFORMATIONALLY-PREORGANIZED, MiniPEG-CONTAINING GAMMA-PEPTIDE NUCLEIC ACIDS | POLL, PCNA, POLG | PI4KA 1915/4885PI4K2B 2188/4885PI4K2A 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.